Sensei Biotherapeutics Advances PIKTOR Oncology Program Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics reported its financial results for the first quarter ended March 31, 2026, while also outlining…
Kariya and NeuraLight Collaborate to Evaluate Brain Effects of Next-Generation GLP-1 Therapies Kariya Pharmaceuticals and NeuraLight have announced a strategic partnership aimed at advancing the development of next-generation brain-focused GLP-1…
Glooko Receives FDA 510(k) Clearance for EndoTool IV Cloud Platform Glooko, Inc., a global digital health company specializing in diabetes management and glycemic safety solutions, has announced that the U.S.…
Worldwide Clinical Trials Expands Leadership Team to Enhance Global Reach and Therapeutic Expertise Worldwide Clinical Trials, a global contract research organization (CRO) focused on delivering specialized clinical development services for…
Affinia Therapeutics Highlights Advances in Gene Therapy Pipeline and Manufacturing at ASGCT 2026 Affinia Therapeutics showcased major progress across its cardiovascular and central nervous system gene therapy programs during multiple…
Ionis and Biogen Report Promising Phase 2 Results for Tau-Targeting Alzheimer’s Therapy Diranersen Ionis Pharmaceuticals and Biogen have announced encouraging topline findings from the Phase 2 CELIA clinical study evaluating…
Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates Adicet Bio has reported financial results and operational progress for the first quarter ended March 31, 2026, highlighting…
Next Health Opens New Peoria Location Offering Advanced Longevity and Preventive Care Services in Arizona Next Health, a provider of preventive wellness, longevity, and personalized health optimization services, has announced…
New Heart Failure 2026 Analyses Highlight Consistent Clinical Benefits of Vutrisiran Across Diverse ATTR-CM Patient Groups Alnylam Pharmaceuticals has announced new analyses from its Phase 3 HELIOS-B clinical trial evaluating…
BeOne Medicines’ BEQALZI™ Receives U.S. FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines has announced that the U.S. Food and Drug Administration has…
Dyno Therapeutics Expands Frontiers Network and Unveils Second Annual Genetic Agency Technology Conference Dyno Therapeutics, a biotechnology company focused on applying artificial intelligence to advance in vivo gene delivery, has…
Medisca and dsm–firmenich Collaborate to Broaden U.S. Access to Pharmaceutical-Grade Vitamin APIs for Compounding Pharmacies Medisca, a global provider of personalized pharmaceutical solutions and compounding technologies, has announced a strategic…